Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure?

Fidelity MSCI Health Care Index ETF (FHLC) is presented as the preferable healthcare-sector ETF versus iShares Global Healthcare ETF (IXJ), with a 0.08% expense ratio versus 0.38% and a 24.0% one-year return versus 16.6%. FHLC also outperformed IXJ on annualized 3-, 5-, and 10-year returns, delivering 11.1%, 5.6%, and 10.8%, respectively, compared with 8.6%, 4.8%, and 9.1% for IXJ. IXJ offers greater international diversification, with 27% of assets outside the U.S., while FHLC is U.S.-only and holds more companies (343 versus 110).

Analysis

The apparent FHLC advantage is not a differentiated healthcare thesis; both vehicles are dominated by the same U.S. mega-cap drug exposure, particularly LLY, JNJ, and ABBV. The lower fee compounds into a modest but reliable structural edge, while FHLC’s broader U.S. mid/small-cap allocation adds more biotech and services beta than IXJ. That makes FHLC preferable only if the intended exposure is domestic innovation and M&A optionality, not simply low-volatility healthcare.

The more consequential decision is whether investors are being adequately paid for concentration in LLY and other large pharmaceutical franchises. A broad healthcare ETF can mask a single-name valuation or reimbursement shock: LLY’s obesity franchise, Medicare drug-pricing implementation, FDA safety developments, and patent-litigation outcomes can drive sector-level returns over the next 1-3 quarters. IXJ’s overseas allocation is not necessarily defensive; it introduces FX risk and greater exposure to slower-growth European pharma without enough weight to materially diversify U.S. policy risk.

Consensus likely overweights trailing return and underweights factor composition. In a risk-off, falling-rate environment, FHLC should outperform IXJ through higher domestic growth exposure; in a dollar decline or a rotation away from expensive U.S. GLP-1 beneficiaries, IXJ’s non-U.S. sleeve could narrow the gap. This is a low-impact fund-selection item rather than a standalone alpha catalyst; ETF flows are unlikely to move underlying constituents.

Key Decisions for Investors

• For strategic U.S. healthcare beta, use FHLC rather than IXJ over a 6-18 month horizon; the fee differential is certain, but position sizing should recognize that both funds retain substantial LLY/JNJ/ABBV overlap.
• Do not initiate a standalone long FHLC/short IXJ pair solely on trailing performance: the expected fee carry is only about 30 bps annually and is insufficient against FX, regional factor, and rebalancing risk.
• For portfolios already overweight LLY, avoid adding FHLC as a "diversifier"; use a more equal-weight healthcare vehicle or add selected providers/managed care exposure instead. Reassess if LLY falls materially on obesity-treatment pricing, safety, or volume guidance revisions.
• Use IXJ only where non-U.S. healthcare exposure is explicitly desired. A sustained weaker USD and relative earnings upgrades at European pharma would be the catalysts for IXJ to outperform over 1-3 months; absent those conditions, its higher cost is a persistent drag.